Abbonarsi

Explainable AI for Parkinson’s disease prediction: A machine learning approach with interpretable models - 12/09/25

Doi : 10.1016/j.retram.2025.103541 
Adebimpe O. Esan a , David B. Olawade b, c, d, e, , Afeez A. Soladoye a , Bolaji A. Omodunbi a , Ibrahim A. Adeyanju a , Nicholas Aderinto f
a Department of Computer Engineering, Federal University, Oye-Ekiti, Nigeria 
b Department of Allied and Public Health, School of Health, Sport and Bioscience, University of East London, London, UK 
c Department of Research and Innovation, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK 
d Department of Public Health, York St John University, London, UK 
e School of Health and Care Management, Arden University, Arden House, Middlemarch Park, Coventry, CV3 4FJ, UK 
f Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria 

Corresponding author.

Highlights

Explainable AI enhances clinical trust in Parkinson’s predictive models.
Random Forest achieves best predictive performance for Parkinson’s Disease.
SHAP clarifies global importance of PD features like UPDRS and cognition.
LIME provides clear, patient-specific explanations of model predictions.
Functional assessment scores strongly influence PD model predictions.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

Parkinson’s Disease (PD) is a chronic, progressive neurological disorder with significant clinical and economic impacts globally. Early and accurate prediction remains challenging with traditional diagnostic methods due to subjectivity, delayed diagnosis, and variability. Machine Learning (ML) approaches offer potential solutions, yet their clinical adoption is hindered by limited interpretability. This study aimed to develop an interpretable ML model for early and accurate PD prediction using comprehensive multimodal datasets and Explainable Artificial Intelligence (XAI) techniques.

Methods

The study applied five ML algorithms: Support Vector Machine (SVM), K-Nearest Neighbors (KNN), Logistic Regression (LR), Random Forest (RF), XGBoost, and a stacked ensemble method to a publicly available dataset ( n = 2105) from Kaggle. Data encompassed demographic, medical history, lifestyle, clinical symptoms, cognitive, and functional assessments with specific inclusion/exclusion criteria applied. Preprocessing involved normalization, Synthetic Minority Oversampling Technique (SMOTE), and Sequential Backward Elimination (SBE) for feature selection. Model performance was evaluated via accuracy, precision, recall, F1-score, and Area Under Curve (AUC). The best-performing model (RF with feature selection) was interpreted using SHAP and LIME methods.

Results

Random Forest combined with Backward Elimination Feature Selection achieved the highest predictive accuracy (93 %), precision (93 %), recall (93 %), F1-score (93 %), and AUC (0.97). SHAP and LIME analyses indicated UPDRS scores, cognitive impairment, functional assessment, and motor symptoms as primary predictors, enhancing clinical interpretability.

Conclusion

The study demonstrated the effectiveness of an interpretable RF model for accurate PD prediction. Integration of ML and XAI significantly improves clinical decision-making, diagnosis timing, and personalized patient care.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Parkinson’s disease, Machine learning, Explainable artificial intelligence, Predictive modeling, Clinical decision-making


Mappa


© 2025  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 73 - N° 4

Articolo 103541- dicembre 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Immunotherapy with ex vivo–expanded donor-derived NK cells after haploidentical HSCT in pediatric patients with AML: a phase I pilot study
  • Tahereh Rostami, Mohammad Ahmadvand, Bahram Chahardoli, Mohammad Reza Rostami, Mojtaba Azari, Morteza Azari, Azadeh Kiumarsi, Ghasem Janbabaei
| Articolo seguente Articolo seguente
  • Optimized GMP-grade Wharton’s jelly’s mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention
  • Cécile Pochon, Romain Perouf, Anne-Béatrice Notarantonio, Allan Bertrand, Naceur Charif, De Carvalho Bittencourt Marcelo, Guillemette Fouquet, Ghislaine Cauchois, Danièle Bensoussan, David Moulin, Simona Pagliuca, Natalia de Isla, Hervé Sartelet, Maud D’Aveni, Marie-Thérèse Rubio

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.